Homepage
Author:
AgomAb Therapeutics N.V.
Posted Date:
April 23, 2026
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
AgomAb Therapeutics N.V.
April 23, 2026
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
AgomAb Therapeutics N.V.
March 26, 2026
Agomab Announces Closing of Initial Public Offering
AgomAb Therapeutics N.V.
February 9, 2026
Agomab Announces Pricing of Initial Public Offering
AgomAb Therapeutics N.V.
February 8, 2026
Agomab Announces Launch of Initial Public Offering
AgomAb Therapeutics N.V.
February 2, 2026
